SBIR/STTR Research Award
FUNGAL EXPRESSION OF DENGUE PROTEINS FOR VACCINES
Award amount
$50,000Program and phase
SBIR · Phase IAward year
1992Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- HAWAII BIOTECH, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- ECJKEEFL4L51
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DENGUE VIRUSES ARE A LEADING CAUSE OF MORBIDITY THROUGHOUT THE TROPICS AND SUBTROPICS. ATTEMPTS TO DEVELOP LIVE ATTENUATED DENGUE VACCINES ANALOGOUS TO THE YELLOW FEVER VACINE HAVE BEEN UNSUCCESSFUL. IN AN EFFORT TO CONTRUBITE TO THE DEVELOPMENT OF A RECOMBINANT SUBUNIT DENGUE VACCINE, WE WILL INVESTIGATE EXPRESSION OF THE DEN-3 ENVELOPE GLYCOPROTEIN IN THE FILAMENTOUS FUNGUS NEUROSPORA CRASSA.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Chikungunya Recombinant Subunit Vaccine
- Development of a Cross-Protective New World Encephalitic Alphavirus Subunit Vaccine
- Novel TLR-4 Agonists as Vaccine Adjuvants
- RECOMBINANT WEST NILE VIRUS VACCINE ADJUVANTED WITH SLA-LSQ
- Chikungunya Recombinant Subunit Vaccine
Research funding history
103 SBIR/STTR records share this UEI (1983–2024). Reported award amounts total $40,917,853. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Defense, National Science Foundation, Department of Agriculture